CTOs on the Move

Synspira

www.synspira.com

 
Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.synspira.com
  • 10 Speen St, 302
    Framingham, MA USA 01701
  • Phone: 617.466.3111

Executives

Name Title Contact Details

Funding

Synspira raised $14M on 10/20/2020

Similar Companies

DBV Technologies

DBV Technologies (DBV) is a clinical-stage biopharmaceutical company focused on discovering safe and effective treatments for patients with food allergies and other unmet medical needs. DBV has developed a proprietary technology platform called Viaskin®, which is based on epicutaneous immunotherapy, or EPIT®, DBV`s method of delivering biologically active compounds to the immune system. This novel mechanism of action accesses the immune system through intact skin without allowing passage of the antigen into the bloodstream. The company is also exploring Viaskin® in other areas of unmet need including vaccines, inflammatory conditions and autoimmune diseases. DBV was founded in 2002 by Dr. Pierre-Henri Benhamou, Chairman and CEO, Dr. Christophe Dupont, Chairman of DBV`s Scientific Advisory Board, and Mr. Bertrand Dupont, Chief Technology Officer.

Geneos Therapeutics

Geneos is developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells.

Healthnet Solutions

Healthnet Solutions is a Bloomfield Hills, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Custom Biogenic Systems

Custom Biogenic Systems is a Romeo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and biologic therapeutics. The Company`s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet.